Reporter brief
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This pilot does not establish whether senolytics are safe or effective for treating Alzheimer's disease—it only addresses whether the drugs can reach the brain tissue in humans
- No efficacy data on cognitive outcomes or disease progression are reported; proof of brain penetration alone does not demonstrate clinical benefit
- As an early-stage proof-of-concept study, results cannot be generalized to broader populations or to other senolytic combinations
Study design and sample
Case report; Human.
Older adults with early Alzheimer's disease
- Design
- Case report
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Mar 6, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.